Equities research analysts forecast that Emergent Biosolutions Inc (NYSE:EBS) will report $264.89 million in sales for the current quarter, Zacks reports. Two analysts have issued estimates for Emergent Biosolutions’ earnings, with the highest sales estimate coming in at $266.18 million and the lowest estimate coming in at $263.60 million. Emergent Biosolutions reported sales of $193.81 million during the same quarter last year, which would suggest a positive year over year growth rate of 36.7%. The firm is scheduled to announce its next earnings report on Thursday, February 28th.
According to Zacks, analysts expect that Emergent Biosolutions will report full year sales of $776.58 million for the current fiscal year, with estimates ranging from $775.30 million to $777.85 million. For the next financial year, analysts expect that the business will post sales of $1.05 billion, with estimates ranging from $993.41 million to $1.13 billion. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow Emergent Biosolutions.
Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported $0.55 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.62 by ($0.07). Emergent Biosolutions had a return on equity of 12.89% and a net margin of 14.19%. The firm had revenue of $173.70 million during the quarter, compared to analysts’ expectations of $185.16 million. During the same quarter in the previous year, the business earned $0.73 earnings per share. The company’s revenue for the quarter was up 16.3% compared to the same quarter last year.
Several research analysts have recently issued reports on the company. Zacks Investment Research restated a “hold” rating on shares of Emergent Biosolutions in a research note on Tuesday, November 13th. Cowen restated a “hold” rating and issued a $64.00 price objective on shares of Emergent Biosolutions in a research note on Tuesday, November 20th. Wells Fargo & Co set a $65.00 price objective on Emergent Biosolutions and gave the stock a “hold” rating in a research note on Wednesday, August 29th. Cantor Fitzgerald set a $62.00 price objective on Emergent Biosolutions and gave the stock a “buy” rating in a research note on Tuesday, August 28th. Finally, Argus set a $80.00 price objective on Emergent Biosolutions and gave the stock a “buy” rating in a research note on Friday, November 9th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $68.13.
In related news, CEO Daniel Abdun-Nabi sold 28,220 shares of Emergent Biosolutions stock in a transaction that occurred on Friday, September 14th. The stock was sold at an average price of $65.00, for a total transaction of $1,834,300.00. Following the completion of the transaction, the chief executive officer now directly owns 194,787 shares in the company, valued at $12,661,155. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Chairman Fuad El-Hibri sold 35,173 shares of Emergent Biosolutions stock in a transaction that occurred on Tuesday, November 20th. The shares were sold at an average price of $69.75, for a total value of $2,453,316.75. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 163,678 shares of company stock valued at $11,030,898. 16.50% of the stock is owned by company insiders.
A number of hedge funds have recently made changes to their positions in EBS. Thompson Siegel & Walmsley LLC acquired a new stake in Emergent Biosolutions in the second quarter valued at approximately $202,000. Pacer Advisors Inc. acquired a new stake in Emergent Biosolutions in the third quarter valued at approximately $205,000. Parametrica Management Ltd acquired a new stake in Emergent Biosolutions in the third quarter valued at approximately $223,000. D.A. Davidson & CO. acquired a new stake in Emergent Biosolutions in the third quarter valued at approximately $224,000. Finally, Family Firm Inc. acquired a new stake in Emergent Biosolutions in the third quarter valued at approximately $225,000. Institutional investors own 81.39% of the company’s stock.
Shares of NYSE:EBS opened at $65.59 on Friday. Emergent Biosolutions has a 52-week low of $42.50 and a 52-week high of $73.89. The stock has a market capitalization of $3.50 billion, a PE ratio of 34.52, a PEG ratio of 1.60 and a beta of 1.26. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.52 and a quick ratio of 4.29.
About Emergent Biosolutions
Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.
See Also: What are retained earnings?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.